New Orally Active Dual Enkephalinase Inhibitors (DENKIs) for Central and Peripheral Pain Treatment - Archive ouverte HAL Access content directly
Journal Articles Journal of Medicinal Chemistry Year : 2014

New Orally Active Dual Enkephalinase Inhibitors (DENKIs) for Central and Peripheral Pain Treatment

(1) , (1) , (1) , (1) , (2)
1
2

Abstract

Protecting enkephalins, endogenous opioid peptides released in response to nociceptive stimuli, is an innovative approach for acute and neuropathic pain alleviation. This is achieved by inhibition of their enzymatic degradation by two membrane-bound Zn-metallopeptidases, neprilysin (NEP, EC 3.4.24.11) and aminopeptidase N (APN, EC 3.4.11.2). Selective and efficient inhibitors of both enzymes, designated enkephalinases, have been designed that markedly increase extracellular concentrations and half-lives of enkephalins, inducing potent antinociceptive effects. Several chemical families of Dual ENKephalinase Inhibitors (DENKIs) have previously been developed but devoid of oral activity. We report here the design and synthesis of new pro-drugs, derived from co-drugs combining a NEP and an APN inhibitor through a disulfide bond with side chains improving oral bioavailability. Their pharmacological properties were assessed in various animal models of pain targeting central and/or peripheral opioid systems. Considering its efficacy in acute and neuropathic pain, one of these new DENKIs, 19-IIIa, was selected for clinical development.
Not file

Dates and versions

hal-03292704 , version 1 (20-07-2021)

Identifiers

Cite

Herve Poras, Elisabeth Bonnard, Emilie Dange, Marie-Claude Fournie-Zaluski, Bernard P. Roques. New Orally Active Dual Enkephalinase Inhibitors (DENKIs) for Central and Peripheral Pain Treatment. Journal of Medicinal Chemistry, 2014, 57 (13), pp.5748-5763. ⟨10.1021/jm500602h⟩. ⟨hal-03292704⟩
22 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More